

**Neuren (NEU) – ASX Announcement****7 February 2025**

## Priority Review Voucher sale proceeds received

**Melbourne, Australia:** Neuren Pharmaceuticals (ASX: NEU) announced that it has today received in cash its one-third share of the net proceeds from the sale of the Rare Pediatric Disease Priority Review Voucher (PRV). Neuren's partner Acadia Pharmaceuticals (NASDAQ: ACAD) successfully completed the sale of the PRV for US\$150m on 11 December 2024.

The PRV was granted to Acadia by the U.S. Food and Drug Administration (FDA) following the approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome. Under the license agreement between Neuren and Acadia, Neuren receives one-third of the proceeds, net of any applicable costs.

### About Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted "orphan drug" designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren's second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

### Contact:

investorrelations@neurenpharma.com

Jon Pilcher, CEO: +61 438 422 271

### ASX Listing Rules information

This announcement was authorized to be given to the ASX by the CEO of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

### Forward-looking Statements

*This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.*